# Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct06008119/  
OnCo record `nct06008119` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tunlametinib run by Shanghai Kechow Pharma, Inc. in colorectal cancer, now recruiting.

## Summary

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT06008119 by Shanghai Kechow Pharma, Inc., with 165 participants planned, started 2023-10-25. Conditions listed: Colorectal Cancer Metastatic. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06008119
- Phase: 3
- Setting: A Multicenter, Randomized, Open-label, Phase 3 Study to Evaluate the Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
- Sponsor: Shanghai Kechow Pharma, Inc.
- Enrolled: 165

## Sources

- ClinicalTrials.gov NCT06008119: https://clinicaltrials.gov/study/NCT06008119

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Tunlametinib](https://onco.cc/drugs/tunlametinib/)
- companies: [Shanghai Kechow Pharma](https://onco.cc/companies/shanghai-kechow-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06008119.json